{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T06:52:27Z","timestamp":1792306347999,"version":"4.4.0"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","award":["21IPA2111845"],"award-info":[{"award-number":["21IPA2111845"]}],"id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1F31AI174773"],"award-info":[{"award-number":["1F31AI174773"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Next-generation pneumococcal conjugate vaccines (PCVs) target an expanding array of serotype antigens. We assessed the proportions of invasive pneumococcal disease (IPD) and pneumococcal acute respiratory infections (ARIs) caused by serotypes targeted by existing and pipeline PCVs, and the annual United States pneumococcal disease burdens potentially preventable by these products.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We estimated serotype distribution and proportions of pneumococcal ARIs (acute otitis media [AOM; children only], sinusitis, nonbacteremic pneumonia) and IPD attributable to serotypes targeted by each PCV using Markov chain Monte Carlo approaches incorporating data from epidemiological studies and Active Bacterial Core surveillance. We then estimated annual numbers of outpatient-managed ARIs, nonbacteremic pneumonia hospitalizations, and IPD cases potentially preventable by PCVs by multiplying disease incidence rates by PCV-targeted disease proportions and vaccine effectiveness estimates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In children, PCV15, PCV20, PCV24, PCV25, and PCV31 serotypes account for 16% (95% confidence interval, 15%\u201317%), 31% (30%\u201332%), 34% (32%\u201335%), 43% (42%\u201344%), and 68% (67%\u201369%) of pneumococcal AOM, respectively. In adults, PCV15, PCV20, PCV21, PCV24, PCV25, and PCV31 serotypes account for 43% (38%\u201347%), 52% (47%\u201357%), 69% (64%\u201373%), 65% (61%\u201370%), 62% (57%\u201367%), and 87% (83%\u201390%) of pneumococcal nonbacteremic pneumonia. For IPD, 42%\u201385% of pediatric and 42%\u201394% of adult cases were due to PCV-targeted serotypes. PCV-preventable burdens encompassed 270 000\u20133 300 000 outpatient-managed ARIs, 2000\u201317 000 pneumonia hospitalizations, and 3000\u201314 000 IPD cases annually.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Across pneumococcal conditions, coverage and preventable burdens were lowest for PCV15 and highest for PCV31, with PCV21 also targeting sizeable burdens of adult disease. Comparative estimates of preventable disease burden may inform future policy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/infdis\/jiaf376","type":"journal-article","created":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T11:19:39Z","timestamp":1753096779000},"page":"e609-e620","source":"Crossref","is-referenced-by-count":18,"title":["Pneumococcal Serotype Distribution and Coverage of Existing and Pipeline Pneumococcal Vaccines"],"prefix":"10.1093","volume":"232","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7785-4712","authenticated-orcid":false,"given":"Laura M","family":"King","sequence":"first","affiliation":[{"name":"School of Public Health, University of California, Berkeley , Berkeley, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin L","family":"Andrejko","sequence":"additional","affiliation":[{"name":"Division of Bacterial Diseases, Centers for Disease Control and Prevention , Atlanta, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9190-5619","authenticated-orcid":false,"given":"Miwako","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Division of Bacterial Diseases, Centers for Disease Control and Prevention , Atlanta, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8498-1149","authenticated-orcid":false,"given":"Wei","family":"Xing","sequence":"additional","affiliation":[{"name":"Division of Bacterial Diseases, Centers for Disease Control and Prevention , Atlanta, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0591-1009","authenticated-orcid":false,"given":"Adam L","family":"Cohen","sequence":"additional","affiliation":[{"name":"Division of Bacterial Diseases, Centers for Disease Control and Prevention , Atlanta, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9300-3045","authenticated-orcid":false,"given":"Wesley H","family":"Self","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Vanderbilt University Medical Center , Nashville, Tennessee ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2062-9615","authenticated-orcid":false,"given":"J Jackson","family":"Resser","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Vanderbilt University Medical Center , Nashville, Tennessee ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1056-3216","authenticated-orcid":false,"given":"Cynthia G","family":"Whitney","sequence":"additional","affiliation":[{"name":"Rollins School of Public Health, Emory University , Atlanta, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrienne","family":"Baughman","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Vanderbilt University Medical Center , Nashville, Tennessee ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Kio","sequence":"additional","affiliation":[{"name":"Department of Medicine, Emory University , Atlanta, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos G","family":"Grijalva","sequence":"additional","affiliation":[{"name":"Department of Health Policy, Vanderbilt University Medical Center , Nashville, Tennessee ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Traenkner","sequence":"additional","affiliation":[{"name":"Department of Medicine, Emory University , Atlanta, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2512-7919","authenticated-orcid":false,"given":"Nadine","family":"Rouphael","sequence":"additional","affiliation":[{"name":"Department of Medicine, Emory University , Atlanta, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph A","family":"Lewnard","sequence":"additional","affiliation":[{"name":"School of Public Health, University of California, Berkeley , Berkeley, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,22]]},"reference":[{"key":"2025101515141464400_jiaf376-B1","author":"Blacklock"},{"key":"2025101515141464400_jiaf376-B2","doi-asserted-by":"crossref","first-page":"512.e1","DOI":"10.1016\/j.cmi.2019.09.008","article-title":"Multistate population and whole genome sequence-based strain surveillance of invasive pneumococci recovered in the USA during 2017","volume":"26","author":"Varghese","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"2025101515141464400_jiaf376-B3","author":"Centers for Disease Control and Prevention"},{"key":"2025101515141464400_jiaf376-B4","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/cid\/ciaa667","article-title":"Unnecessary antibiotic prescribing in US ambulatory care settings, 2010\u20132015","volume":"72","author":"Hersh","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2025101515141464400_jiaf376-B5","first-page":"1","article-title":"Changes in outpatient antibiotic prescribing for acute respiratory illnesses, 2011 to 2018","volume":"1","author":"King","year":"2021","journal-title":"Antimicrob Steward Healthc Epidemiol"},{"key":"2025101515141464400_jiaf376-B6","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM200102083440602","article-title":"Efficacy of a pneumococcal conjugate vaccine against acute otitis media","volume":"344","author":"Eskola","year":"2001","journal-title":"N Engl J Med"},{"key":"2025101515141464400_jiaf376-B7","doi-asserted-by":"crossref","first-page":"e289","DOI":"10.1093\/cid\/ciz1164","article-title":"Dose-specific effectiveness of 7- and 13-valent pneumococcal conjugate vaccines against vaccine-serotype Streptococcus pneumoniae colonization in children","volume":"71","author":"Lewnard","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2025101515141464400_jiaf376-B8","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1093\/infdis\/jiac098","article-title":"Effectiveness of pneumococcal conjugate vaccination against virus-associated lower respiratory tract infection among adults: a case-control study","volume":"227","author":"Lewnard","year":"2023","journal-title":"J Infect Dis"},{"key":"2025101515141464400_jiaf376-B9","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.15585\/mmwr.mm7239a5","article-title":"ACIP updates: recommendations for use of 20-valent pneumococcal conjugate vaccine in children\u2014United States, 2023","volume":"72","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2025101515141464400_jiaf376-B10","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.15585\/mmwr.mm7137a3","article-title":"Use of 15-valent pneumococcal conjugate vaccine among U.S. children: updated recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2022","volume":"71","author":"Kobayashi","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2025101515141464400_jiaf376-B11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7203a1","article-title":"Pneumococcal vaccine for adults aged \u226519 years: recommendations of the Advisory Committee on Immunization Practices, United States, 2023","volume":"72","author":"Kobayashi","year":"2023","journal-title":"MMWR Recomm Rep"},{"key":"2025101515141464400_jiaf376-B12","author":"Centers for Disease Control and Prevention"},{"key":"2025101515141464400_jiaf376-B13","first-page":"1361","article-title":"Persistent circulation of vaccine serotypes and serotype replacement after 5 years of infant immunization with 13-valent pneumococcal conjugate vaccine in the United Kingdom","volume":"221","author":"Kandasamy","year":"2020","journal-title":"J Infect Dis"},{"key":"2025101515141464400_jiaf376-B14","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/S0140-6736(10)62225-8","article-title":"Serotype replacement in disease after pneumococcal vaccination","volume":"378","author":"Weinberger","year":"2011","journal-title":"Lancet"},{"key":"2025101515141464400_jiaf376-B15","doi-asserted-by":"crossref","first-page":"e213","DOI":"10.1016\/S1473-3099(18)30660-1","article-title":"Making sense of differences in pneumococcal serotype replacement","volume":"19","author":"Lewnard","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2025101515141464400_jiaf376-B16","doi-asserted-by":"crossref","first-page":"e1423","DOI":"10.1093\/cid\/ciaa1860","article-title":"Effectiveness of pneumococcal conjugate vaccines against community-acquired alveolar pneumonia attributable to vaccine-serotype Streptococcus pneumoniae among children","volume":"73","author":"Lewnard","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2025101515141464400_jiaf376-B17","doi-asserted-by":"crossref","first-page":"e00329","DOI":"10.1128\/JCM.00329-21","article-title":"New pneumococcal serotype 15D","volume":"59","author":"Pimenta","year":"2021","journal-title":"J Clin Microbiol"},{"key":"2025101515141464400_jiaf376-B18","author":"Centers for Disease Control and Prevention"},{"key":"2025101515141464400_jiaf376-B19","first-page":"838","article-title":"Prevalence, clinical severity, and serotype distribution of pneumococcal pneumonia among adults hospitalized with community-acquired pneumonia in Tennessee and Georgia, 2018\u20132022","volume":"79","author":"Self","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2025101515141464400_jiaf376-B20","author":"US Food and Drug Administration"},{"key":"2025101515141464400_jiaf376-B21","author":"Merck Sharp & Dohme LLC"},{"key":"2025101515141464400_jiaf376-B22","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1016\/j.vaccine.2024.04.061","article-title":"Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease among children in the United States between 2010 and 2019: an indirect cohort study","volume":"42","author":"Andrejko","year":"2024","journal-title":"Vaccine"},{"key":"2025101515141464400_jiaf376-B23","doi-asserted-by":"crossref","first-page":"7207","DOI":"10.1016\/j.vaccine.2011.06.056","article-title":"The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A","volume":"29","author":"Cooper","year":"2011","journal-title":"Vaccine"},{"key":"2025101515141464400_jiaf376-B24","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1016\/j.vaccine.2024.03.065","article-title":"Effects of PCV10 and PCV13 on pneumococcal serotype 6C disease, carriage, and antimicrobial resistance","volume":"42","author":"Grant","year":"2024","journal-title":"Vaccine"},{"key":"2025101515141464400_jiaf376-B25","author":"Self"},{"key":"2025101515141464400_jiaf376-B26","doi-asserted-by":"crossref","first-page":"4872","DOI":"10.1016\/j.vaccine.2022.06.041","article-title":"Streptococcus pneumoniae serotype 15B polysaccharide conjugate elicits a cross-functional immune response against serotype 15C but not 15A","volume":"40","author":"Hao","year":"2022","journal-title":"Vaccine"},{"issue":"Suppl 2","key":"2025101515141464400_jiaf376-B27","doi-asserted-by":"crossref","first-page":"ofad500.1560","DOI":"10.1093\/ofid\/ofad500.1560","article-title":"Immune responses to cross-reactive serotypes 6C and 15C after 20-valent pneumococcal conjugate vaccine in infants","volume":"10","author":"Tamimi","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"2025101515141464400_jiaf376-B28","author":"Centers for Disease Control and Prevention"},{"key":"2025101515141464400_jiaf376-B29","author":"Healthcare Cost and Utilization Project. Overview of the National (Nationwide) Inpatient Sample (NIS)","year":"2025"},{"key":"2025101515141464400_jiaf376-B30","first-page":"821","article-title":"Outpatient visits and antibiotic use due to higher-valency pneumococcal vaccine serotypes","volume":"230","author":"King","year":"2024","journal-title":"J Infect Dis"},{"key":"2025101515141464400_jiaf376-B31","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1093\/cid\/ciaa529","article-title":"Incidence of pharyngitis, sinusitis, acute otitis media, and outpatient antibiotic prescribing preventable by vaccination against group A Streptococcus in the United States","volume":"73","author":"Lewnard","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2025101515141464400_jiaf376-B32","author":"Centers for Disease Control and Prevention"},{"key":"2025101515141464400_jiaf376-B33","author":"Centers for Disease Control and Prevention"},{"key":"2025101515141464400_jiaf376-B34","author":"Centers for Disease Control and Prevention"},{"key":"2025101515141464400_jiaf376-B35","author":"Lucero"},{"key":"2025101515141464400_jiaf376-B36","doi-asserted-by":"crossref","first-page":"e1434","DOI":"10.1093\/cid\/ciaa1867","article-title":"Impact of pneumococcal conjugate vaccine on vaccine serotype\u2013specific pneumonia","volume":"73","author":"Klugman","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2025101515141464400_jiaf376-B37","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1016\/j.vaccine.2023.03.045","article-title":"Public health impact and cost-effectiveness of 15-valent pneumococcal conjugate vaccine use among the pediatric population of the United States","volume":"41","author":"Prasad","year":"2023","journal-title":"Vaccine"},{"key":"2025101515141464400_jiaf376-B38","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa1408544","article-title":"Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults","volume":"372","author":"Bonten","year":"2015","journal-title":"N Engl J Med"},{"key":"2025101515141464400_jiaf376-B39","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1097\/INF.0000000000004334","article-title":"A phase three study of the safety and immunogenicity of a four-dose series of 20-valent pneumococcal conjugate vaccine in healthy infants","volume":"43","author":"Senders","year":"2024","journal-title":"Pediatr Infect Dis J"},{"key":"2025101515141464400_jiaf376-B40","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1093\/cid\/ciab990","article-title":"Pivotal phase 3 randomized clinical trial of the safety, tolerability, and immunogenicity of 20-valent pneumococcal conjugate vaccine in adults aged \u226518 years","volume":"75","author":"Essink","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2025101515141464400_jiaf376-B41","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/S1473-3099(23)00572-8","article-title":"Evaluating the safety, tolerability, and immunogenicity of a 24-valent pneumococcal conjugate vaccine (VAX-24) in healthy adults aged 18 to 64 years: a phase 1\/2, double-masked, dose-finding, active-controlled, randomised clinical trial","volume":"24","author":"Wassil","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"2025101515141464400_jiaf376-B42","doi-asserted-by":"crossref","first-page":"126124","DOI":"10.1016\/j.vaccine.2024.07.025","article-title":"A phase 2, randomized, blinded, dose-finding, controlled clinical trial to evaluate the safety, tolerability, and immunogenicity of a 24-valent pneumococcal conjugate vaccine (VAX-24) in healthy adults 65 years and older","volume":"42","author":"Wassil","year":"2024","journal-title":"Vaccine"},{"key":"2025101515141464400_jiaf376-B43","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1016\/j.vaccine.2022.05.079","article-title":"Phase 1\/2 study of a novel 24-valent pneumococcal vaccine in healthy adults aged 18 to 64 years and in older adults aged 65 to 85 years","volume":"40","author":"Chichili","year":"2022","journal-title":"Vaccine"},{"key":"2025101515141464400_jiaf376-B44","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1016\/j.vaccine.2024.02.001","article-title":"Safety, tolerability and immunogenicity of a novel 24-valent pneumococcal vaccine in toddlers: a phase 1 randomized controlled trial","volume":"42","author":"Borys","year":"2024","journal-title":"Vaccine"},{"key":"2025101515141464400_jiaf376-B45","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1093\/cid\/cit428","article-title":"Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial","volume":"57","author":"Dagan","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2025101515141464400_jiaf376-B46","doi-asserted-by":"crossref","first-page":"7265","DOI":"10.1016\/j.vaccine.2023.10.054","article-title":"Naturally-induced serum antibody levels in children to pneumococcal polysaccharide 15B that correlate with protection from nasopharyngeal colonization but anti-serotype 15B antibody has low functional cross-reactivity with serotype 15C","volume":"41","author":"Kaur","year":"2023","journal-title":"Vaccine"},{"key":"2025101515141464400_jiaf376-B47","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S1473-3099(24)00344-X","article-title":"Safety, tolerability, and immunogenicity of an adult pneumococcal conjugate vaccine, V116 (STRIDE-3): a randomised, double-blind, active comparator controlled, international phase 3 trial","volume":"24","author":"Platt","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"2025101515141464400_jiaf376-B48","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1097\/INF.0000000000004413","article-title":"Anticipated effects of higher-valency pneumococcal conjugate vaccines on colonization and acute otitis media","volume":"43","author":"Kaur","year":"2024","journal-title":"Pediatr Infect Dis J"},{"key":"2025101515141464400_jiaf376-B49","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1093\/infdis\/jiaa501","article-title":"Upsurge of conjugate vaccine serotype 4 invasive pneumococcal disease clusters among adults experiencing homelessness in California, Colorado, and New Mexico","volume":"223","author":"Beall","year":"2021","journal-title":"J Infect Dis"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiaf376\/63816343\/jiaf376.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/232\/4\/e609\/63816343\/jiaf376.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/232\/4\/e609\/63816343\/jiaf376.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T19:16:15Z","timestamp":1760555775000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/232\/4\/e609\/8210159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,22]]},"references-count":49,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,7,22]]},"published-print":{"date-parts":[[2025,10,15]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiaf376","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.12.12.24318944","asserted-by":"object"}]},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10,15]]},"published":{"date-parts":[[2025,7,22]]}}}